Multidrug-resistant Acinetobacter baumannii pneumonia in lung transplant recipients.
We present 6 cases of multidrug-resistant (MDR) Acinetobacter baumannii pneumonia in lung transplant recipients. All cases were treated with imipenem and/or non-traditional antibiotics, such as tigecycline and colistimethate, and had different microbiologic and clinical outcomes. Prior treatment with broad-spectrum anti-microbial therapy was the single most likely risk factor for the development of infection due to MDR Acinetobacter baumannii. Ideal preventive and therapeutic strategies for this pathogen in lung transplant recipients require further study.
Sopirala
Madhuri M
MM
Department of Internal Medicine, Division of Infectious Diseases, The Ohio State University Medical Center, Columbus, OH 43210, USA. madhuri.sopirala@osumc.edu
Pope-Harman
Amy
A
Nunley
David R
DR
Moffatt-Bruce
Susan
S
Ross
Patrick
P
Martin
Stanley I
SI
D000151:Acinetobacter Infections / Q000188:drug therapy* / Q000382:microbiology*; D040981:Acinetobacter baumannii; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D003091:Colistin / Q000031:analogs & derivatives / Q000627:therapeutic use; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D016040:Lung Transplantation / Q000009:adverse effects*; D008297:Male; D008911:Minocycline / Q000031:analogs & derivatives / Q000627:therapeutic use; D011014:Pneumonia / Q000188:drug therapy* / Q000382:microbiology*; D012307:Risk Factors; D000078304:Tigecycline; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D000078304:Tigecycline; D015378:Imipenem; C004691:colistinmethanesulfonic acid; D008911:Minocycline; D003091:Colistin